Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes

Pivotal trial established use of AspyreRx alongside standard of care demonstrating clinically meaningful and statistically significant reduction in HbA1c leading to FDA authorization


In a subgroup...

Related Keywords

United States ,American ,Marc Bonaca ,Frank Karbe ,Exchange Commission ,Clinical Research ,Outcomes Research ,Better Therapeutics Inc ,Drug Administration ,Nasdaq ,Health Economics ,Better Therapeutics ,Executive Director ,Regulatory Considerations ,Prescription Drug Use Related Software ,Better Therapeutic ,Markets ,